A multimodal prehabilitation program for the reduction of post-operative complications after surgery in advanced ovarian cancer under an ERAS pathway: a randomized multicenter trial (SOPHIE)Berta Díaz-Feijoo, Nuria Agusti, Raquel Sebio, Marina Sisó, Núria Carreras-Dieguez, Santiago Domingo, Oscar Díaz-Cambronero, Aureli Torne, Graciela Martinez-Palli, Ma José Arguís
6 July 2022
CERVANTES: an international randomized trial of radical surgery followed by adjuvant (chemo) radiation versus no further treatment in patients with early-stage, intermediate-risk cervical cancer (CEEGOG-CX-05; ENGOT-CX16)David Cibula, Martina Borčinová, Roman Kocian, David Feltl, Sona Argalacsova, Pavel Dvorak, Daniela Fischerová, Pavel Dundr, Jiri Jarkovsky, Eva Höschlová, Jiri Slama, Giovanni Scambia
13 September 2022
ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiationCarmen Garcia-Duran, Francisco Grau, Guillermo Villacampa, Ana Oaknin
20 April 2022
CHRONO: randomized trial of the CHROnology of surgery after Neoadjuvant chemotherapy for Ovarian cancerJean-Marc Classe, Gwennael Ferron, Lobna Ouldamer, Tristan Gauthier, Sheik Emambux, Laurence Gladieff, Pierre-Francois Dupre, Amélie Anota
23 March 2022
Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic/persistent/recurrent ovarian cancer: a prospective, multicenter phase II study (MITO-RT3/RAD)Gabriella Macchia, Barbara Alicja Jereczek-Fossa, Roberta Lazzari, Annamaria Cerrotta, Francesco Deodato, Edy Ippolito, Cynthia Aristei, Maria Antonietta Gambacorta, Giovanni Scambia, Vincenzo Valentini, Gabriella Ferrandina
21 June 2021
Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groupsClorinda Schettino, Lucia Musacchio, Michele Bartoletti, Paolo Chiodini, Laura Arenare, Gustavo Baldassarre, Daniela Califano, Ettore Capoluongo, Maria Paola Costi, Maurizio D'Incalci, Sergio Marchini, Delia Mezzanzanica, Nicola Normanno, Stefania Scala, Stefano GreggiSee the full list of authors
22 March 2022
Sentinel lymph node mapping versus sentinel lymph node mapping with systematic lymphadenectomy in endometrial cancer: an open-label, non-inferiority, randomized trial (ALICE trial)Glauco Baiocchi, Carlos Eduardo Mattos Cunha Andrade, Reitan Ribeiro, Renato Moretti-Marques, Audrey Tieko Tsunoda, Vanessa Alvarenga-Bezerra, Andre Lopes, Ronaldo Lúcio Rangel Costa, Lillian Yuri Kumagai, Levon Badiglian-Filho, Carlos Chaves Faloppa, Henrique Mantoan, Louise De Brot, Ricardo Dos Reis, Bruna Tirapelli Goncalves
2 March 2022
Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancerPaul A Cohen, Penelope M Webb, Madeleine King, Andreas Obermair, Val Gebski, Phyllis Butow, Rachael Morton, Wanda Lawson, Patsy Yates, Rachel Campbell, Tarek Meniawy, Michelle McMullen, Andrew Dean, Jeffrey Goh, Orla McNallySee the full list of authors
22 September 2021
PROPER—PRehabilitatiOn Plus Enhanced Recovery after surgery versus enhanced recovery after surgery in gynecologic oncology: a randomized clinical trialAndre Lopes, Alayne Magalhães Trindade Domingues Yamada, Thais de Campos Cardenas, Jaqueline Nunes de Carvalho, Emília de Azevedo Oliveira, Marina Elisa Ribeiro da Silva, Juliana Fenerich Mauri Andrade, Eduardo de Souza Neto, Lilian Arruda do Rêgo Barros, Ronaldo Lúcio Rangel Costa
8 November 2021
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001Christian Marth, Rafal Tarnawski, Alexandra Tyulyandina, Sandro Pignata, Lucy Gilbert, Diego Kaen, M Jesús Rubio, Sophia Frentzas, Mario Beiner, Manuel Magallanes-Maciel, Laura Farrelly, Chel Hun Choi, Regina Berger, Christine Lee, Christof VulstekeSee the full list of authors
19 November 2021